



Richard Byrd Pollard, M.D.

Philosophy of Care	My philosophy of care is comprehensive primary care of HIV-infected patients and patients with other infectious diseases.
Clinical Interests	Dr. Pollard's clinical research includes usage of new antiviral drugs, the care of HIV-infected patients, HIV vaccines as well as clinical immunology. Pollard's research interests include immunology of viral infections, immune responses to HIV, CMV, HPV, and VZV as well as immunologic non-responders.
Title	Professor
Specialty	Infectious Diseases, Internal Medicine
Department	Internal Medicine
Division	Infectious Diseases
Center/Program Affiliation	Northern California Center for AIDS Research
Address/Phone	Lawrence J. Ellison Ambulatory Care Center, Infectious Diseases Clinic, 4860 Y St. Suite 0101 Sacramento, CA 95817 Phone: 916-734-2737
	CARES Clinic, 1500 21st St. Sacramento, CA 95811 Phone: 800-2-UCDAVIS
Additional Phone	Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Education	M.D., University of Maryland School of Medicine, Baltimore, Maryland, 1970
Internships	Ohio State University, Columbus, Ohio, 1970-71
Residency	Emory University, Atlanta, Georgia, 1973-75
Fellowships	Stanford University Medical Center, Stanford, California, 1975-78
Board Certifications	American Board of Internal Medicine, 1975
Professional Memberships	American Association of Immunologists American College of Physicians, Fellow



Richard Byrd Pollard, M.D.

Infectious Diseases Society of America, Fellow
Sigma Xi

Honors and Awards

Best Doctors in America, 2010
Best Doctors in America, 2009
Best Doctors in America, 2007

Select Recent Publications

Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottitil S, Cramer Y, Chan ES, Schooley RT, Rinaldo CR, Thielman N, Li XD, Wahl SM, Shore J, Janik J, Lempicki RA, Simpson Y, Pollard RB; and the AIDS Clinical Trials Group A5192 Team.. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. *Journal of Infectious Diseases*, 201(11): 1686-1696, 2010.

Ferre AL, Lemongello D, Hunt PW, Morris MM, Garcia JC, Pollard RB, Yee HFJr, Martin JN, Deeks SG, and Shacklett BL. Immunodominant HIV-Specific CD8 +T-Cell Responses Are Common to Blood and Gastrointestinal Mucosa, and Gag-Specific Responses Dominate in Rectal Mucosa of HIV Controllers. *Journal of Virology*, 84(19): 10354-10365, 2010.

Kalayjian R, Machezano R, Rizk N, Robbins G, Gandhi R, Rodriguez B, Pollard RB, Lederman M, and Landay A. Pre-treatment levels of soluble receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. *Journal of Infectious Diseases*, 201(12): 1796-1805, 2010.

Lennox JL, DeJesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H, Gilbert CL, Tepler H, Rodgers AJ, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Sklar P, and the STARTMRK Investigators. Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses. *Journal of Acquired Immune Deficiency Syndrome*, 2010 Apr 15. [Epub ahead of print], 2010.

Schacker T, Bosch R, Bennett K, Pollard RB, Robbins G, Collier A, Gulick R, Spritzler J, and Mildvan D. Measurement of Naive CD4 Cells Reliably Predicts Potential for Immune Reconstitution in HIV. *Journal of Acquired Immune Deficiency Syndrome*, 54(1): 59-62, 2010.

Smith K, Zheng L, Bosch R, Margolis D, Tenorio A, Napolitano L, Saag M, Connick E, Lawrence J, Gross B, Francis I, Valdez H, Wang R, Muurahainen N, Stocker V, Pollard RB.. Treatment with recombinant growth hormone is associated with enhanced CD4 lymphocyte reconstitution in HIV-infected subjects with incomplete immune reconstitution on HAART—results of adult AIDS clinical trial group protocol (AACTG) 5174. *AIDS Res Human Retrovir*, 26(4): 425-432, 2010.

Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JVR, Berger DS, Zhao J, Xu X, Williams-



Richard Byrd Pollard, M.D.

Diaz A, Rodgers AJ, O'Barnard RJ, Miller MD, DiNubile MJ, Nguyen BY, Leavitt R, and Sklar P, for the STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. *The Lancet*, 374(9692): 796-806, 2009.

Meier A, Chang JJ, Chan ES, Pollard RB, Sidhu HK, Kulkarni S, Wen TF, Orellana L, Mildvan D, Bazner S, Streeck H, Alter G, Lifson JD, Carrington M, Bosch RJ, Robbins GK, and Altfeld M. Sex differences in the TLR-mediated response of pDCs to HIV-1 are associated with higher immune activation in infected women. *Nature Medicine*, 15(8): 955-959, 2009.

Gupta SK, Komarow L, Gulick RM, Pollard RB, Robbins GK, Franceschini N, Szczech LA, Koletar SL, and Kalayjian RC. Proteinuria, Creatinine Clearance, and Immune Activation in Antiretroviral-Naive HIV-Infected Subjects. *The Journal of Infectious Diseases*, 200: 614-618, 2009.

Crawford K, Spritzler J, Kalayjian R, Parsons T, Landay A, Pollard RB, Stocker V, Lederman M, Flexner C.. Age-related changes in pharmacokinetic parameters of the HIV protease inhibitor lopinavir. *AIDS Res Human Retrovir*, 2009.

Yoshida T, Kobayashi M, Li XD, Pollard RB, and Suzuki F. Inhibitory effect of glycyrrhizin on the neutrophil-dependent increase of R5 HIV replication in cultures of macrophages. *Immunology and Cell Biology*, 2009(Jun 16): Epub ahead of print, 2009.

© 2015 UC Regents